Ocrelizumab - Biogen/Genentech
Alternative Names: 2H7-monoclonal-antibody; 2nd Generation Anti-CD20; Anti-CD20 monoclonal antibody - Genentech; Humanised Anti-CD20 mAb; Monoclonal-antibody-2H7; OCR; OCRE; Ocrevus; Ocrevus SC; PRO 70769; R 1594; RG 1594; rhuMab 2H7; RO4964913Latest Information Update: 15 Apr 2025
At a glance
- Originator Biogen Idec; Genentech
- Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Roche
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Urologics
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis
- Discontinued Eye disorders; Haematological malignancies; Lupus nephritis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 02 Apr 2025 Adverse events and efficacy data from a phase-III MUSETTE trial in Multiple sclerosis released by Roche
- 27 Feb 2025 Efficacy and adverse event data from a phase III trial for Multiple Sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS-2025)
- 27 Feb 2025 Updated adverse events and efficacy data from the phase-III OCARINA II trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS-2025)